Plain-English translation of NCT04712305 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether urine samples can help predict how well immunotherapy will work for advanced kidney cancer and what side effects you might experience. By analyzing special markers in your urine before and during treatment, they hope to develop a tool that could personalize your care and help doctors anticipate problems early.
Right now, doctors cannot reliably predict which patients will benefit from immunotherapy or who will experience severe side effects. This study aims to discover urine-based markers that could help doctors choose the best treatment approach for each patient and monitor them more carefully.
You likely qualify if…
You likely don't qualify if…
You will donate fresh urine samples at the beginning of the study and at follow-up visits while you receive your immunotherapy treatment. The study will be divided into two phases: an initial training phase (first 24 months) to identify which urine markers predict treatment response, followed by a validation phase (next 36 months) to confirm those findings. Your participation helps researchers develop a better way to predict how you and other patients will respond to treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Taiwan
Sponsor
National Taiwan University Hospital
Enrollment target
~400 participants
Started
January 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years and older
Last updated on clinicaltrials.gov in January 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yeong Shiau Pu, MD PhD
National Taiwan University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.